About CAMBRIDGENE LIMITED
CAMBRIDGENE LIMITED is a Private Limited Company and was incorporated on Mar 16, 2015 in Germany. Its corporate identification number is (CIN) 9493568 and its current status is Active.
Key Metrics
CIN
9493568
Current Status
Active
Entity Type
Private Limited Company
Date Of Incorporation
Mar 16, 2015
Latest Employee Count
1 as on Mar 31, 2024
Brands associated with CAMBRIDGENE LIMITED
There is one brand associated with CAMBRIDGENE LIMITED which include Cambridgene .
Name | Short Description | Founded Year | Location | Current Stage |
|---|---|---|---|---|
Provider of integrative multi-omics solutions for healthcare | 2013 | Funding Raised |
Financials of CAMBRIDGENE LIMITED
Competitors & Alternates of CAMBRIDGENE LIMITED
Cambridgene is the only brand associated with CAMBRIDGENE LIMITED, and here are its Top 10 competitors ranked by Tracxn score:
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Seer 2017, San Francisco (United States), Public | Developer of proteomics platform for early detection of cancer and neurological diseases | $128M | 72/100 | |
2nd |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 71/100 | |
3rd | Maze Therapeutics 2018, Redwood City (United States), Public | Developer of genetic bio-markers in neurological, metabolic, and renal diseases | $496M | 66/100 | |
4th | Metabolon 2000, Morrisville (United States), Series H | Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine | $166M | 66/100 | |
5th | Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public | Developer of small molecule drugs for diffrent health diseases | - | 64/100 | |
6th |  Wobble Genomics 2020, Edinburgh (United Kingdom), Series A | Provider of a platform for discovery of nucleic acid biomarkers | $12.5M | 62/100 | |
7th | Oxford Biodynamics 2007, Oxford (United Kingdom), Public | Developer of personalized diagnostics by identifying biomarkers through epigenetics | $11M | 56/100 | |
8th |  Proteomics International 2001, Perth (Australia), Public | Medical technology company at the forefront of predictive diagnostics and bio-analytical services | - | 55/100 | |
9th | Denovo Biopharma 2013, San Diego (United States), Series D | Developer of genomic biomarker discovery platform | $172M | 55/100 | |
10th | Valirx 2000, London (United Kingdom), Public | Developer of novel technologies and products in oncology therapeutics and diagnostics | - | - | 53/100 |
87th | Cambridgene 2013, Cambridge (United Kingdom), Funding Raised | Provider of integrative multi-omics solutions for healthcare | - | 17/100 |
Attribution:
Auszug aus dem Unternehmensregister July 24, 2026
FAQs about CAMBRIDGENE LIMITED
Explore our recently published Legal Entities
